Back to Browse Journals » OncoTargets and Therapy » Volume 2

Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer

Authors Francesco Di Costanzo, Silvia Gasperoni, Virginia Rotella, Federica Di Costanzo

Published Date July 2009 Volume 2009:2 Pages 179—188

DOI http://dx.doi.org/10.2147/OTT.S3863

Published 7 July 2009

Francesco Di Costanzo,1 Silvia Gasperoni,1 Virginia Rotella,1 Federica Di Costanzo2

1Struttura Complessa Oncologia Medica, Azienda Ospedaliero Universitaria Careggi, Florence; 2Servizio di Oncologia: Ospedale S: Maria della Stella, Orvieto, Italy

Abstract: Taxanes are chemotherapeutic agents with a large spectrum of antitumor activity when used as monotherapy or in combination regimens. Paclitaxel and docetaxel have poor solubility and require a complex solvent system for their commercial formulation, Cremophor EL® (CrEL) and Tween 80® respectively. Both these biological surfactants have recently been implicated as contributing not only to the hypersensitivity reactions, but also to the degree of peripheral neurotoxicity and myelosuppression, and may antagonize the cytotoxicity. Nab-paclitaxel, or nanoparticle albumin-bound paclitaxel (ABI-007; Abraxane®), is a novel formulation of paclitaxel that does not employ the CrEL solvent system. Nab-paclitaxel demonstrates greater efficacy and a favorable safety profile compared with standard paclitaxel in patients with advanced disease (breast cancer, non-small cell lung cancer, melanoma, ovarian cancer). Clinical studies in breast cancer have shown that nab-paclitaxel is significantly more effective than standard paclitaxel in terms of overall objective response rate (ORR) and time to progression. Nab-paclitaxel in combination with gemcitabine, capecitabine or bevacizumab has been shown to be very active in patients with advanced breast cancer. An economic analysis showed that nab-paclitaxel would be an economically reasonable alternative to docetaxel or standard paclitaxel in metastatic breast cancer. Favorable tumor ORR and manageable toxicities have been reported for nab-paclitaxel as monotherapy or in combination treatment in advanced breast cancer.

Keywords: breast cancer, nab-paclitaxel, chemotherapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

The comparison of protein-entrapped liposomes and lipoparticles: preparation, characterization, and efficacy of cellular uptake

Chang WK, Tai YJ, Chiang CH, Hu CS, Hong PD, Yeh MK

International Journal of Nanomedicine 2011, 6:2403-2417

Published Date: 20 October 2011

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval

Yamamoto Y, Kawano I, Iwase H

OncoTargets and Therapy 2011, 4:123-136

Published Date: 18 July 2011

Reversible exposure of hydrophobic residues on albumin as a novel strategy for formulation of nanodelivery vehicles for taxanes

Garro AG, Beltramo DM, Alasino RV, Leonhard V, Heredia V, Bianco ID

International Journal of Nanomedicine 2011, 6:1193-1200

Published Date: 13 June 2011

Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis

Safaa Sebak, Maryam Mirzaei, Meenakshi Malhotra, et al

International Journal of Nanomedicine 2010, 5:525-532

Published Date: 15 September 2010

Health literacy and health seeking behavior among older men in a middle-income nation

Paul A Bourne, Chloe Morris, Christopher AD Charles, et al

Patient Related Outcome Measures 2010, 1:39-49

Published Date: 26 May 2010

Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer

Evelina Miele, Gian Paolo Spinelli, Ermanno Miele, Federica Tomao, Silverio Tomao

International Journal of Nanomedicine 2009, 4:99-105

Published Date: 27 April 2009

Problems and barriers of pain management in the emergency department: Are we ever going to get better?

Sergey M Motov, Abu NGA Khan

Journal of Pain Research 2009, 2:5-11

Published Date: 9 December 2008

Capillary telangiectasia mimicking an active inflammatory MS-lesion in repetitive cMRIs

Michael Harzheim, Claudia Gemmel, Bernd Sommer, Ulf Kallweit, Dieter Pöhlau

Reports in Medical Imaging 2008, 1:1-2

Published Date: 24 November 2008